A recent paper published in Nature Aging indicates that epigenetic reprogramming could potentially reverse the human aging process. However, lead authors were quick to emphasize that the complete eradication of biological death remains strictly theoretical and requires further longitudinal study.
While early trials funded by Altos Labs utilizing Yamanaka factors appear to cure hundreds of age-related diseases in laboratory mice, researchers stress that the findings are entirely preliminary. Health officials have formally advised the public not to assume they will live forever until large-scale clinical trials can establish a reliable baseline for permanent human existence, noting that eternal life could carry unforeseen mild-to-moderate side effects.
While returning a 90-year-old human to the biological health of a toddler is a promising early indicator, we must remember that immortality has not yet been evaluated in a double-blind, placebo-controlled setting.
At present, the FDA has not approved epigenetic cellular rejuvenation for the routine treatment of mortality. Medical professionals advise patients who are currently experiencing aging to continue doing so at a normal, steady rate until peer-reviewed safety data on living forever can be adequately assessed.